Personalised Medicine 2013 - Signalling Pathways

Oncology Meeting Resources

01 Mar - 03 Mar, Sitges, Spain

Signalling Pathways 2014

Please find below the links to all Signalling Pathways in Cancer 2013 presentations that have an abstract, slide set or webcast. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Search Meeting Resources by Keyword



Useful links

Presenter Presentation title Session title
Jean-Yves Douillard ESMO Educational activities: From past to future. Focus on personalized medicine Introduction
Yossi Yarden The principles of signal transduction (focus on concepts of signalling, perturbation, opportunities for intervention) The basis of targeted therapy
Giampaolo Tortora Mechanisms of primary and secondary resistance The basis of targeted therapy
Livio Trusolino Tumor patient derived models (“xenopatients”) Pre-clinical models
Aleix Prat Characterization of one disease in different subtypes (breast cancer as an example) Dissecting the field of biomarkers
Federico Rojo Pitfalls and challenges with tumor tissue specimens Dissecting the field of biomarkers
Giuseppe Curigliano Tumor-host interaction: Focus on immune response and microenvironment Dissecting the field of biomarkers
Fortunato Ciardiello Pharmacology basis of targeted therapy Clinical pharmacology concepts of targeted therapy
Josep Tabernero How to maximize smart clinical development from phase I Clinical pharmacology concepts of targeted therapy
Andres Cervantes Ruiperez ESMO Guidelines: How deep we go in personalized medicine Guidelines
Josep Tabernero New opportunities for EGFR-pathway inhibition (focus on new compounds and combinations to avoid cross-talk and resistance) Colorectal cancer
Monica Arnedos Ballester Characterization of HER-2/neu breast cancer Breast cancer
Fatima Cardoso The hallmark of trastuzumab in the treatment of breast cancer Breast cancer
Christoph Zielinski Is there a role for personalization between trastuzumab and lapatinib? Breast cancer
Luca Gianni Adjuvant and neoadjuvant strategies in HER-2/neu disease Breast cancer